Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jinghua Wang maintains a focused patent portfolio in the Biotechnology & Pharmaceuticals sector, currently featuring 1 pending office action. The prosecution is consolidated under 1 distinct examiner, SHOMER, ISAAC, who accounts for 1 pending office action. This concentration suggests that the portfolio's immediate progress depends entirely on the examiner's review process rather than a broader departmental trend. Such a narrow focus allows for a very specific and consistent legal strategy that targets the examiner's known requirements.
The data shows that all current activity is confined to 1 distinct art unit. For a practitioner, this means that the prosecution strategy does not currently need to account for varying art unit cultures or multiple examiner styles. Success in this technology area is presently tied to the specific interactions with the assigned examiner. This streamlined environment allows for a highly targeted approach to overcoming rejections, as the applicant only needs to satisfy the requirements of the specific official within the USPTO. The lack of administrative complexity facilitates a more direct path toward potential allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 1 | 63.1% | +30.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17908086 | DIFFUSIVITY CONTRAST AGENTS FOR MEDICAL IMAGING | SHOMER, ISAAC | 3d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17908086 | DIFFUSIVITY CONTRAST AGENTS FOR MEDICAL IMAGING | SHOMER, ISAAC | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17908086 | DIFFUSIVITY CONTRAST AGENTS FOR MEDICAL IMAGING | SHOMER, ISAAC | 1612 | §101§112 | Non-Final OA | 3d overdue | Pending | Aug 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJinghua Wang has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Isaac Shomer has the most, with 1 of Jinghua Wang's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
